10-Q: Bluejay Diagnostics Reports Q1 2025 Results, Cites Going Concern Uncertainty and Need for $30 Million Capital Raise

Bluejay Diagnostics' Q1 2025 results reveal a net loss of $1.86 million and highlight substantial doubt about the company's ability to continue as a going concern without securing significant additional funding.

Summary

• Bluejay Diagnostics, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is focused on developing rapid tests using its Symphony technology platform for critical care settings.
• Bluejay Diagnostics has not yet received regulatory clearance for its Symphony platform from the FDA.
• The company incurred a net loss of $1.86 million for the three months ended March 31, 2025, compared to a net loss of $2.33 million for the same period in 2024.
• Research and development expenses decreased to $0.8 million from $1.3 million year-over-year.
• General and administrative expenses remained relatively stable at approximately $1.1 million.
• The company had cash and cash equivalents of $3.12 million and current liabilities of $1.32 million as of March 31, 2025.
• Bluejay Diagnostics has an accumulated deficit of $36.53 million as of March 31, 2025.
• The company expects to need to raise at least $30 million between Q2 2025 and the end of 2027 to execute its plan.
• Bluejay Diagnostics anticipates submitting a 510(k) regulatory application to the FDA in Q4 2027, with potential FDA approval as early as Q3 2028.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company estimates its current cash resources will be sufficient to fund operations until Q3 2025.
• Bluejay Diagnostics is planning to begin cartridge redevelopment either at an in-house facility or through a third-party contractor.
• The company has slowed the timeline of its clinical trial work to preserve cash resources in the near-term, which will delay its Symphony platform regulatory submission timeline until Q4 2027, at the earliest.

Sentiment

Score: 3

Explanation: The document presents a concerning financial outlook for Bluejay Diagnostics, with significant losses, a going concern warning, and a need for substantial capital raising. While there are some positive aspects, such as decreased R&D expenses, the overall sentiment is negative due to the company's financial instability and dependence on future funding.

Positives

• The net loss decreased from $2.33 million in Q1 2024 to $1.86 million in Q1 2025.
• Research and development expenses decreased, indicating potential cost management.
• The company successfully completed a warrant inducement transaction in April 2025, raising approximately $3.8 million in gross proceeds.

Negatives

• The company has a significant accumulated deficit of $36.53 million as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company needs to raise a significant amount of capital ($30 million) to execute its strategic plan.
• The company has slowed the timeline of its clinical trial work to preserve cash resources in the near-term, which will delay its Symphony platform regulatory submission timeline until Q4 2027, at the earliest.
• The company has downsized its organization, which may reduce business continuity, affect its ability to apply for certain patents, and affect its product development and timelines, including its previously disclosed plan to transfer underlying production of its cartridges to an in-house facility for redevelopment.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Failure to obtain regulatory approval for the Symphony platform would significantly impact the company's prospects.
• Delays in clinical trials and product development could push back the timeline for FDA submission and approval.
• The company's reliance on third-party manufacturers (CMOs) poses supply chain risks.
• The company has downsized its organization, which may reduce business continuity, affect its ability to apply for certain patents, and affect its product development and timelines, including its previously disclosed plan to transfer underlying production of its cartridges to an in-house facility for redevelopment.
• The company is currently negotiating an upcoming separation with its Chief Technology Officer, who is also significantly involved in these matters, its ongoing SYMON-II clinical studies, analytical studies, and certain intellectual property in connection with the prior development work of Symphony performed by Company.

Future Outlook

The company expects to need to raise at least $30 million between the second quarter of 2025 and the end of the 2027 fiscal year to execute its plan, which includes submitting a 510(k) regulatory application to the FDA in the fourth quarter of 2027 and achieving FDA approval as early as the third quarter of 2028.

Management Comments

• The company is working on developing rapid tests using whole blood on its Symphony technology platform.
• The company is planning to begin cartridge redevelopment either at an in-house facility or through a third-party contractor.
• The company expects that its net cash used in operating activities will continue to be negative over at least the next several years.
• The company currently estimates that the cash resources it possesses as of the date of this filing will be sufficient to fund its operations up to the third quarter of 2025.

Industry Context

The medical diagnostics industry is highly competitive and subject to rapid technological change. Bluejay Diagnostics faces competition from larger biotechnology companies. The company's success depends on obtaining regulatory approval for its Symphony platform and successfully commercializing its products.

Comparison to Industry Standards

• It is difficult to compare Bluejay Diagnostics directly to industry standards due to its pre-revenue stage and focus on a specific technology platform.
• Comparable companies in the diagnostics space, such as QuidelOrtho or Roche, have established revenue streams and a broader product portfolio.
• Bluejay's success hinges on the clinical performance of its Symphony IL-6 test and its ability to secure regulatory approval, which are key benchmarks for companies in this sector.
• The $30 million capital raise target is significant for a company of Bluejay's size and reflects the high cost of developing and commercializing medical diagnostic products.

Management Changes

Related Party Transactions

• The company entered into a settlement and release agreement with NanoHybrids, LLC, an entity in which the company's Chief Technology Officer, Jason Cook, served as Chief Executive Officer of prior to joining Bluejay.
• The company agreed to make payment of $50,000 to Nanohybrids and reimburse Nanohybrids for up to $30,000 in reasonable and documented attorneys fees that Nanohybrids had previously incurred in connection with the Strategic Transaction Discussions.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential liquidation.
• Employees are impacted by downsizing and potential job losses.
• Customers (healthcare providers) may face uncertainty regarding the availability of the Symphony platform.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to begin testing of samples it is collecting as part of its ongoing SYMON-II clinical trial in mid-2027.
• The company aims to submit a 510(k) regulatory application to the FDA in the fourth quarter of 2027.
• The company is exploring potential pathways to raise additional material capital.
• The company is planning to begin cartridge redevelopment either at an in-house facility or through a third-party contractor.

Key Dates

Keywords

Bluejay Diagnostics, Symphony platform, IL-6 test, FDA approval, clinical trials, capital raise, going concern, financial results, regulatory submission, reverse stock split